Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Nutritionists create interesting recipes to carry forward this evidence
Regulatory Context Research Use Status KLOW is not FDA approved for any therapeutic indication
Study population We prospectively enrolled 61 non-ambulatory SMA children at six centers in North America
Key Findings from the Clinical Trial The study, led by Christian Hendershot at USC's Institute for Addiction Science, showed that weekly injections of semaglutide compared to placebo: Reduced alcohol cravings significantly Decreased drinking quantity overall Lowered the frequency of heavy drinking days What makes these results particularly exciting is that the magnitude of semaglutide's effects appeared potentially greater than what is typically seen with existing FDA-approved medications for alcohol use disorder, even though the drug was only administered at the lowest clinical doses
US$ 23.10
US$ 27.95
US$ 27.46
US$ 24.33
